CTLA4 and metastatic melanoma: Clinical trials combining checkpoint therapy with cellular vaccines are also ongoing, such as a phase I trial combining MART-126–35-loaded DC injection with anti-CTLA-4 (tremelimumab) in metastatic melanoma patients (76) and with anti-PD-1 (nivolumab) in patients with recurrent brain tumors (NCT02529072).